


Persistent function based machine learning for drug design

Xiang Liu

Nankai University

December 8, 2023

Drug Discovery Process (Simplified)



Discovery

Development

Use

Med. Chem. ML,

Clinical Candidates

Drugs

>450,000 distinct compounds
~25,000 distinct lead series

~12,000 candidates


~1,200 drugs

Time: > 10 years

Cost: > 2.6 billion\$

High failure rate

Drug discovery is a challenging search problem



Number of possible drug-like molecules $\approx 10^{60}$
obeying Lipinski's rule-of-five for oral bioavailability

AI in drug design and discovery

nature

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe

nature > spotlight > article

SPOTLIGHT | 30 May 2018

How artificial intelligence is changing drug discovery

Machine learning and other technologies are expected to make the hunt for new pharmaceuticals quicker, cheaper and more effective.

Nic Fleming

How AI could revolutionize drug discovery

November 16, 2022 | Video

By Alex Devereson, Christoph Sandler, and Lydia The

Share Print Download Save

Artificial intelligence could help scientists develop better medicines faster—and thus improve millions of people's lives.

But for that to happen, companies will need to change the way they work.

Exscientia

ABOUT

PATIENT-FIRST AI

PIPELINE

INVESTORS & MEDIA

JOIN US

[View All News](#)

Exscientia Announces [First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials](#)

April 9, 2021

Company's technologies and drug-hunting expertise now responsible for world's first and second AI-designed drugs in testing

Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed through a Joint Venture between Exscientia and Evotek. The application of Exscientia's next generation 3-D evolutionary AI-design platform as part of Centaur Chemist®.

The screenshot shows a news article from the 'nature' magazine website. The title is 'How artificial intelligence is changing drug discovery'. Below the title is a blue box containing the text: 'Machine learning and other technologies are expected to make the hunt for new pharmaceuticals quicker, cheaper and more effective.' The author's name, Nic Fleming, is listed at the bottom left. There are sharing options at the bottom right: Share, Print, Download, Save.

The screenshot shows a news article from 'INSIDER INTELLIGENCE' and 'eMarketer'. The title is 'Big pharma is using AI and machine learning in drug discovery and development to save lives'. At the top, there is a search bar and navigation links for Industries, Products, Insights, Events, Pricing, and About. Below the title, there is a section titled 'BEHIND THE NUMBERS' with the subtext 'Made possible by Tinuiti'. To the right, there is a callout for 'Explore the rapidly changing world of digital advertising, media, commerce, and technology.' and a link to 'Listen In'. At the bottom, there are two smaller sections: one with the text 'AI and Machine Learning in Drug Discovery' and another with the text 'Powerful data and analysis on nearly every digital topic'.

Artificial Intelligence

Enabling machines to think like humans

Machine Learning

Training machines to get better at a task without explicit programming

Deep Learning

Using multi-layered networks
for machine learning


Feature extraction and feature learning

“The success of machine learning algorithms generally depends on data representation...”

Y. Bengio, etc, “Representation Learning: A Review and New Perspectives


“The deep learning research aims at discovering learning algorithms that discover multiple levels of distributed representations...”

Y. Bengio, “Deep Learning of Representations: Looking Forward



Molecular Descriptors in QSAR models

More than 5000 Molecular descriptors in Quantitative Structure Activity relationship (QSAR) models.



Grisoni F, Ballabio D, Todeschini R, et al.
Molecular descriptors for structure–activity applications: a hands-on approach[M]//
Computational Toxicology. Humana Press, New York, NY, 2018: 3-53.


Common chemical descriptors for QSAR/QSPR analysis

Chemical descriptors	Based on	Examples
Theoretical descriptors		
0D	Molecular formula	Molecular weights, atom counts, bond counts
1D	Chemical graph	Fragment counts, functional group counts
2D	Structural topology	Weiner index, Balaban index, Randic index, BCUTS
3D	Structural geometry	WHIM, autocorrelation, 3D-MORSE, GETAWAY
4D	Chemical conformation	Volsurf, GRID, Raptor
Experimental descriptors		
Hydrophobic parameters	Hydrophobicity	Partition coefficients ($\log P$), hydrophobic substituent constant (π)
Electronic parameters	Electronic properties	Acid dissociation constant, Hammett constant
Steric parameters	Steric properties	Taft steric constant, Charton's constant

Topological Data Analysis (TDA)

Topological invariant:
Homology Group
Homotopy Group
Cohomology Ring
Steenrod Module

.....



Klein bottle



Torus



Double Torus




Knot




Sphere

Topological Data Analysis---- Persistent Homology




$$f_1=0.4$$

$$\beta_0: 6 \quad \beta_1: 0$$




$$f_2=0.5$$

$$\beta_0: 3 \quad \beta_1: 1$$




$$f_3=0.6$$

$$\beta_0: 1 \quad \beta_1: 1$$




$$f_4=0.8$$

$$\beta_0: 1 \quad \beta_1: 1$$




$$\beta_0 = 2 \quad \beta_1 = 1 \quad \beta_2 = 1$$




Persistent Homology Analysis of Carbon-60


(Xia, Feng, Tong & Wei, JCC, 2015)




β_0



β_1





β_2




Biomolecular Topological Fingerprints

(Xia & Wei, IJNMBE, 2014)
TF for alpha helix







Slicing method



TDA based machine learning models

(Pun, Lee and Xia, AIR, 2021)




Recent progress of TDA based drug design

Guowei Wei




MSU Foundation professor




DUD database 128374 protein-ligand/decoy pairs



Prediction correlations for 2648 mutations on globular proteins (Cang & Wei, PLOS CS, 2017)



Prediction RMSD of logP(star set)



Recent progress of TDA based drug design

Drug Design Data Resource (D3R)
Grand Challenges

D3R Grand Challenge 2

Stage 1

[Pose Predictions \(partials\)](#)

[Scoring \(partials\)](#)

[Free Energy Set 1 \(partials\)](#)

[Free Energy Set 2 \(partials\)](#)

Stage 2



[Scoring \(partials\)](#)

[Free Energy Set 1 \(partials\)](#)


[Free Energy Set 2 \(partials\)](#)

D3R Grand Challenge 3 (2017-2018)

Pose Prediction

Cathepsin Stage 1A
[Pose Predictions \(partials\)](#)

Cathepsin Stage 1B
[Pose Prediction](#)



Affinity Rankings excluding Kds > 10 μM

Cathepsin Stage 1
[Scoring \(partials\)](#)

Free Energy Set

VEGFR2

[Scoring \(partials\)](#)

JAK2 SC3

[Scoring](#)

Free Energy Set

Active / Inactive Classification

VEGFR2

[Scoring \(partials\)](#)

JAK2 SC3

[Scoring](#)

Free Energy Set

Cathepsin Stage 2
[Scoring \(partials\)](#)

Free Energy Set

JAK2 SC2

[Scoring \(partials\)](#)

TIE2

[Scoring](#)

Free Energy Set 2



p38-a
[Scoring \(partials\)](#)

ABL1
[Scoring \(partials\)](#)

Scoring (partials)

Free Energy Set

JAK2 SC2

[Scoring \(partials\)](#)

TIE2

[Scoring \(partials\)](#)

Free Energy Set 1

Affinity Rankings for Cocrystallized Ligands

Cathepsin Stage 1
[Scoring \(partials\)](#)

Free Energy Set

Cathepsin Stage 2

[Scoring \(partials\)](#)

Free Energy Set

D3R Grand Challenge 4 (2018-2019)

Pose Predictions

BACE Stage 1A

[Pose Predictions \(Partials\)](#)

BACE Stage 1B

[Pose Prediction \(Partials\)](#)

Affinity Predictions


Cathepsin Stage 1

[Combined Ligand and Structure Based Scoring](#)

[Ligand Based Scoring \(No participation\)](#)

[Structure Based Scoring](#)

[Free Energy Set](#)



BACE Stage 1

[Combined Ligand and Structure \(No participation\)](#)

[Ligand Based Scoring \(Partials\) \(No participation\)](#)

[Structure Based Scoring \(Partials\) \(No participation\)](#)

[Free Energy Set \(No participation\)](#)

BACE Stage 2


[Combined Ligand and Structure](#)

[Ligand Based Scoring \(No participation\)](#)

[Structure Based Scoring \(Partials\)](#)

[Free Energy Set](#)

TDA-based learning models in SARS-CoV-2



Mutations Strengthened SARS-CoV-2 Infectivity

Wei's Team predicts key mutation sites in prevailing variants

Mutations at 501 and 452 in prevailing SARS-CoV-2 variants

Jiahui Chen¹, Rui Wang¹, Menglun Wang¹ and Guo-Wei Wei^{1,2,3}

¹ - Department of Mathematics, Michigan State University, MI 48824, USA

² - Department of Electrical and Computer Engineering, Michigan State University, MI 48824, USA

³ - Department of Biochemistry and Molecular Biology, Michigan State University, MI 48824, USA

Correspondence to Guo-Wei Wei: wei@math.msu.edu

<https://doi.org/10.1016/j.jmb.2020.07.009>

Edited by Anna Panchenko

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is a major concern in coronavirus disease 2019 (COVID-19) prevention and economic reopening. However, rigorous determination of SARS-CoV-2 infectivity is very difficult owing to its continuous evolution with over 10,000 single nucleotide polymorphisms (SNP) variants in many subtypes. We employ an algebraic topology-based machine learning model to quantitatively evaluate the binding free energy changes of SARS-CoV-2 spike glycoprotein (S protein) and host angiotensin-converting enzyme 2 receptor following mutations. We reveal that the SARS-CoV-2 virus becomes more infectious. Three out of six SARS-CoV-2 subtypes have become slightly more infectious, while the other three subtypes have significantly strengthened their infectivity. We also find that SARS-CoV-2 is slightly more infectious than SARS-CoV according to computed S protein-angiotensin-converting enzyme 2 binding free energy changes. Based on a systematic evaluation of all possible 3686 future mutations on the S protein receptor-binding domain, we show that most likely future mutations will make SARS-CoV-2 more infectious. Combining sequence alignment, probability analysis, and binding free energy calculation, we predict that a few residues on the receptor-binding motif, i.e., 452, 489, 500, 501, and 505, have high chances to mutate into significantly more infectious COVID-19 strains.

Received 4 June 2020;

Received in revised form 9 July 2020;

Accepted 17 July 2020;

Alpha: N501Y

Beta: K417N, E484K, N501Y

Gamma: K417T, E484K, N501Y

Delta: L452R, T478K

Epsilon: L452R

Kappa: L452R, E484Q


Omicron: N501,...

They discovered the mechanism of viral transmission and evolution: more infectious


Why is TDA so powerful ?

Representation


Graph



Simplicial complex



Filtered simplicial complex




Featurization

Topological invariants


Homology Group
Homotopy Group
Cohomology Ring
Steenrod Module

.....


Persistent barcode




Persistent diagram




Graph




Simplicial complex



Hypergraph



Super-hypergraph



Jie Wu,
BIMSA

Hypergraph based data representation


Grbic J, Wu J, Xia K, Wei GW. Aspects of topological approaches for data science[J]. Foundations of Data Science, 2022.

Bressan, Li, Ren, Wu. The embedded homology of hypergraphs and applications , 2016
Ren, Shiquan, et al. "Computing the Homology of Hypergraphs." *arXiv preprint arXiv:1705.00151* (2017).

Ren, Shiquan, Chengyuan Wu, and Jie Wu. "Operators on random hypergraphs and random simplicial complexes." *arXiv preprint arXiv:1712.02045* (2017).

Ren, Shiquan, and Jie Wu. "Stability of persistent homology for hypergraphs." *arXiv preprint arXiv:2002.02237* (2020).

Ren, Shiquan, et al. "A Discrete Morse Theory for Hypergraphs." *arXiv preprint arXiv:1804.07132* (2018).



Embedded homology of hypergraph

Definition (infimum chain complex)

Given a hypergraph \mathcal{H} , the infimum chain complex of \mathcal{H} with coefficient R is defined as

$$\text{Inf}_n(\mathcal{H}, R) = \sum \{ C_n \mid C_\star \text{ is a subchain complex of } R((K_{\mathcal{H}})_\star) \text{ and } C_n \subset R(\mathcal{H}_n) \}$$

which is the largest subchain complex of the chain complex of $K_{\mathcal{H}}$ that is contained in the graded modules $R(\mathcal{H}_\star)$


Definition (supremum chain complex)

Given a hypergraph \mathcal{H} , the supremum chain complex of \mathcal{H} with coefficient R is defined as


$$\text{Sup}_n(\mathcal{H}, R) = \bigcap \{ C_n \mid C_\star \text{ is a subchain complex of } R((K_{\mathcal{H}})_\star) \text{ and } R(\mathcal{H}_n) \subset C_n \}$$

which is the smallest subchain complex of the chain complex of $K_{\mathcal{H}}$ that contains $R(\mathcal{H}_\star)$ as a graded modules.

Bressan, Li, Ren, Wu. AJM, 2019



Hypergraph \mathcal{H}



Associated
simplicial complex
 $K_{\mathcal{H}}$

Proposition

Given a hypergraph \mathcal{H} , the homology of the infimum chain complex and supremum chain complex of \mathcal{H} with coefficient R are isomorphic.

Definition (Hypergraph embedded homology)

Given a hypergraph \mathcal{H} , the n -th embedded homology of \mathcal{H} with coefficient R is defined as

$$H_n(\mathcal{H}, R) = H_n(\text{Sup}_\star(\mathcal{H}, R)) = H_n(\text{Inf}_\star(\mathcal{H}, R))$$

$$C_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$C_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$C_2 = Z\{\{0,1,2\}\}$$


$$A_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$A_1 = Z\{\{0,1\}, \{0,2\}, \{1,2\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$A_2 = Z\{\{0,1,2\}\}$$

$$\rightarrow A_3 \xrightarrow{\partial_3} A_2 \xrightarrow{\partial_2} A_1 \xrightarrow{\partial_1} A_0$$

$$S_n = C_n + \partial_{n+1}(C_{n+1}), I_n = C_n \cap \partial_n^{-1}(C_{n-1})$$



$$I_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$I_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}\}$$

$$I_2 = 0$$

$$S_0 = Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\}$$

$$S_1 = Z\{\{0,1\}, \{2,3\}, \{2,4\}, \{3,4\}, \partial\{0,1,2\}\}$$

$$S_2 = Z\{\{0,1,2\}\}$$

$$H_0^s = Ker(\partial_0^s) / Im(\partial_1^s)$$

$$= S_0 / Im(\partial_1^s)$$

$$= Z\{\{0\}, \{1\}, \{2\}, \{3\}, \{4\}\} / Z\{\{1\} - \{0\}, \{3\} - \{2\}, \{4\} - \{2\}, \{4\} - \{3\}\}$$

$$= I_0 / Im(\partial_1^i)$$

$$= Ker(\partial_0^i) / Im(\partial_1^i)$$

$$= H_0^i$$

$$H_1^s = Ker(\partial_1^s) / Im(\partial_2^s)$$

$$= Z\{\{3,4\} - \{2,4\} + \{2,3\}, \partial\{0,1,2\}\} / Z\{\partial\{0,1,2\}\}$$

$$= Z\{\{3,4\} - \{2,4\} + \{2,3\}\}$$

$$= Ker(\partial_1^i) / Im(\partial_2^i)$$

$$= H_1^i$$

$$H_2^s = Ker(\partial_2^s) / Im(\partial_3^s)$$

$$= Ker(\partial_2^s)$$

$$= 0$$


$$= Ker(\partial_2^i) / Im(\partial_3^i)$$

$$= H_2^i$$


Protein-ligand interaction modeled as hypergraph

Liu, Wang, Wu, Xia,
BIB, 2021


Hypergraph-based models



Hypergraph-based filtration




Bipartite graph VS Hypergraph




Benchmark testing with PDBbind datasets


Model setting:
homology vectors
+
Gradientboostingtree



Dataset 2007






Dataset 2013



Dataset 2016


Persistent function based machine learning

Data




Representation


Simplicial complex: Neighborhood complex, Dowker complex,...




Polyhedral complex: Hom complex...



Hypergraph, Super-hypergraph ...




Algebraic representation: face ring...




Featurization


Persistent homology



Persistent Spectral




Persistent Tor-algebra





Learning

Machine learning: Random Forest, GBT, SVM,...



Deep learning: Convolutional neural network,...



Thank You!